Watcher / research, page-3

In the short term, cashflow is everything to this share price.

• The products themselves are amazing and will only continue to build market share.
• New (doctor/hospital) customers are likely to be very sticky once on board.
• Patent protection extends for a very long time.
• Gross margin is very high and is being maintained year after year.
• Slowly but surely we are seeing highly positive independent studies being published.
• The Canadian study will be the game changer.

But we can't have any more backwards moves and we need to get to operating cashflow positive and soon thereafter overall cashflow positive.

IF and when we get there, "in my view" there will be no stopping the share price.